Innate Pharma (IPH) Status Update summary

Advances in Immunotherapy and Immune Cell Engagement

• Next-generation immunotherapies are leveraging NK cells, T cells, and myeloid cells to overcome resistance and improve efficacy in cancer treatment.

• Novel multispecific engagers, such as trispecific and tetraspecific NK cell engagers (ANKETs), are being developed to target tumor antigens and activate NK cells, with promising preclinical and early clinical results.

• CAR-NK cell therapies, especially those from umbilical cord blood, offer scalable, off-the-shelf, and safer alternatives to autologous CAR-T therapies, with encouraging remission rates and lower toxicity.

• Costimulatory bispecific antibodies targeting CD28 and tumor antigens provide targeted T cell activation, showing efficacy in solid tumors but also autoimmune toxicities.

• Myeloid cell expansion and reprogramming, particularly in aging and cancer, are linked to tumor progression, with IL-1 and Nrf2 pathways as potential therapeutic targets.

Mechanisms of Resistance and Immune Modulation

• Loss of MHC class I expression in tumors leads to resistance to T cell-based therapies but can attract NK cells, unless inhibited by molecules like HLA-G.

• Mutations in antigen presentation machinery genes, such as NLRC5 and CIITA, are associated with reduced responses to immune checkpoint blockade.

• Tumor-induced myelopoiesis and suppressive macrophage recruitment contribute to immune evasion, influenced by IL-4, Nrf2, and DNMT3A downregulation, especially in aged hosts.

• Combination strategies, including cytokine modulation, checkpoint inhibitors, and myeloid-targeted therapies, are being explored to enhance immune cell infiltration and anti-tumor memory.

• The tumor microenvironment, including myeloid and lymphoid cell interactions, is a key determinant of immunotherapy outcomes.

Clinical Translation and Future Directions

• Early-phase clinical trials of NK cell engagers (e.g., IPH6501) and CAR-NK therapies show high efficacy and favorable safety in hematologic malignancies, with ongoing studies in solid tumors.

• Costimulatory bispecifics show promise in turning immunologically cold tumors hot, but require careful management of autoimmune toxicities.

• Targeting myeloid cell expansion and function, particularly through IL-1 and Nrf2 pathways, is being investigated for cancer therapy and prevention, especially in aging.

• Off-the-shelf, banked NK cell products significantly reduce manufacturing costs compared to autologous CAR-T, increasing accessibility.

• Future research will focus on combinatorial approaches, improved patient selection, and understanding immune cell interplay with the tumor microenvironment.